AdComm Will Tussle With Donanemab’s High ARIA Rate in June 10 Meeting

Eli Lilly will make a case for its antiamyloid antibody donanemab on June 10, trying to reassure the Peripheral and Central Nervous System Advisory Committee that the drug is safe, despite the serious adverse events related to the deaths of five people during the drug’s pivotal phase 3 trial.
Source: Drug Industry Daily